Hub : Traits :

Qualifications: None of the above

726 significantly associated models · 136 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	43073464	45157738	12	3	2.0e-13	2.2e-15	3.1e-01	98	MED8 RP11-7O11.3 ST3GAL3
2	1	71163715	73435171	1	1	4.8e-10	4.2e-09	4.0e-04	64	NEGR1
3	1	92957826	94426916	3	1	1.4e-09	2.9e-07	8.8e-01	100	TMED5
4	1	109316076	110716511	1	1	6.3e-08	7.4e-07	4.5e-02	84	SYPL2
5	2	43899918	45698128	1	1	3.6e-09	8.4e-10	4.7e-02	90	CAMKMT
6	2	99922967	101731705	3	1	6.8e-09	6.5e-09	1.4e-01	93	CHST10
7	2	106725928	108199394	1	1	1.2e-07	1.9e-07	1.0e+00	100	ST6GAL2
8	3	16154636	17814553	1	1	2.2e-08	2.7e-09	1.8e-02	84	PLCL2
9	3	48268509	51009435	26	2	2.2e-15	2.1e-13	1.2e-01	96	GPX1 RBM6
10	3	52047421	53860103	3	1	1.7e-07	3.5e-08	8.0e-02	90	NEK4
11	3	107181540	108633112	1	1	1.0e-07	2.0e-06	1.4e-01	90	IFT57
12	3	124558741	125238099	1	1	1.9e-07	7.7e-08	1.4e-01	92	SLC12A8
13	4	2233366	3740612	2	1	2.7e-07	5.6e-08	3.7e-07	12	MFSD10
14	4	105598022	107092169	1	1	3.0e-09	3.2e-09	1.3e-02	82	PPA2
15	5	26181001	27729100	1	1	2.2e-07	6.9e-09	2.3e-04	60	CDH9
16	5	59193824	61156570	5	2	1.9e-17	3.2e-17	7.0e-01	100	ELOVL7
17	5	87006055	88875673	2	2	4.5e-10	7.9e-17	2.0e-08	55	CTC-498M16.2 MEF2C
18	5	176132977	177591495	3	1	5.9e-09	1.0e-08	1.0e+00	100	DBN1
19	6	87530372	88997402	1	1	2.8e-08	2.4e-08	1.0e+00	100	RARS2
20	7	23913624	25432157	1	1	3.5e-08	2.2e-08	1.0e+00	100	MPP6
21	8	30012514	31433801	1	1	1.8e-07	9.3e-08	1.0e-01	91	TEX15
22	8	142629143	144515639	2	3	2.2e-10	6.9e-11	4.9e-03	81	THEM6 TSNARE1
23	9	111008699	112472083	1	1	2.5e-07	2.2e-06	3.3e-02	80	CTNNAL1
24	10	10349662	12076043	1	1	1.6e-08	7.7e-08	1.0e-02	77	CELF2
25	10	64195778	65911294	4	1	3.4e-15	1.6e-15	1.1e-03	83	NRBF2
26	10	102853189	104242886	2	1	2.6e-08	1.0e-08	1.5e-03	69	NPM3
27	10	133048749	134482926	2	2	7.8e-10	2.2e-12	8.7e-01	100	BNIP3 PPP2R2D
28	11	94805896	96276010	4	1	1.9e-13	2.9e-13	2.2e-01	97	AP001877.1
29	11	116805204	117308936	1	1	6.5e-08	1.2e-04	6.5e-01	99	SIDT2
30	12	49556303	50927881	1	1	4.7e-08	4.9e-05	3.0e-02	71	BCDIN3D
31	12	55677395	57125879	5	1	5.4e-11	1.9e-10	1.0e+00	100	SUOX
32	12	122258047	124591385	13	2	1.4e-13	6.2e-12	6.6e-01	100	CDK2AP1 RSRC2
33	13	31078511	32595740	1	1	2.2e-07	1.7e-06	1.8e-01	92	B3GALTL
34	14	73853137	75366447	1	1	5.6e-08	3.0e-06	8.3e-04	49	LIN52
35	16	86671	1432491	1	1	1.4e-07	1.0e-06	7.4e-01	100	WDR24
36	16	24614505	25167985	1	1	1.5e-07	9.1e-09	1.6e-03	70	SLC5A11
37	16	27655848	29595483	19	1	3.6e-10	8.8e-10	5.3e-01	99	SULT1A1
38	16	52828325	54235440	2	1	2.5e-08	6.7e-09	8.6e-02	91	RBL2
39	17	34815551	35675511	1	1	1.5e-07	1.3e-06	5.4e-04	49	CTB-75G16.3
40	19	45064435	46506809	2	1	1.3e-11	1.5e-11	1.0e+00	100	CKM

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.87	2	0	0.0	0.00	1.0e+00	MPP6 NEK4
Bipolar Disorder or Schizophrenia	2.36	7	1	2.2	0.19	6.9e-01	CDK2AP1 ELOVL7 MED8 MPP6 NEK4 PLCL2 RP11-7O11.3
Depressed Affect (Nagel 2018)	3.30	5	2	4.4	0.70	1.9e-01	CDH9 CELF2 GPX1 PLCL2 RBM6
Depression (Nagel 2018)	2.61	2	0	0.0	0.00	1.0e+00	NRBF2 PLCL2
Intelligence (Savage-Jansen 2018)	8.44	29	16	35.6	-0.95	1.9e-16	AP001877.1 BNIP3 CAMKMT CDH9 CDK2AP1 CHST10 CKM CTB-75G16.3 DBN1 ELOVL7 GPX1 IFT57 MED8 NEGR1 NPM3 NRBF2 PLCL2 PPA2 PPP2R2D RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Neuroticism (Nagel 2018)	2.72	8	2	4.4	0.51	1.9e-01	B3GALTL CDH9 CELF2 CTC-498M16.2 GPX1 PLCL2 THEM6 TSNARE1
Schizophrenia (2018)	2.30	4	0	0.0	0.63	2.6e-01	CDK2AP1 ELOVL7 MED8 RP11-7O11.3
Worry (Nagel 2018)	2.45	5	2	4.4	0.63	2.6e-01	AP001877.1 B3GALTL CTC-498M16.2 PLCL2 TSNARE1
Crohns Disease (2017)	1.91	3	2	4.4	0.00	1.0e+00	GPX1 NEK4 SULT1A1
Irritable Bowel Disease (IBD)	2.26	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 SULT1A1
Ulcerative Colitis (UC)	2.18	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 SULT1A1
Major Depression (MDD)	2.83	2	1	2.2	0.00	1.0e+00	GPX1 NEGR1
Verbal and Numeric Reasoning (VNR)	7.64	22	11	24.4	-0.97	6.9e-14	CDH9 CHST10 CKM CTB-75G16.3 DBN1 ELOVL7 GPX1 IFT57 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Breast Cancer	1.24	1	0	0.0	0.00	1.0e+00	GPX1
Prostate Cancer	1.31	2	0	0.0	0.00	1.0e+00	GPX1 PPA2
Age at First Birth	3.89	3	2	4.4	0.00	1.0e+00	CHST10 GPX1 RBM6
Body Mass Index (BMI) (2010)	3.01	3	2	4.4	0.00	1.0e+00	CTB-75G16.3 NEGR1 SULT1A1
Crohns Disease (2012)	1.90	2	2	4.4	0.00	1.0e+00	GPX1 SULT1A1
HDL Cholesterol	1.61	2	1	2.2	0.00	1.0e+00	NRBF2 TMED5
LDL Cholesterol	1.53	1	0	0.0	0.00	1.0e+00	SIDT2
Primary Biliary Cirrhosis	1.22	1	0	0.0	0.00	1.0e+00	PLCL2
Schizophrenia (2014)	2.29	4	1	2.2	-0.30	7.0e-01	CDK2AP1 ELOVL7 PLCL2 TSNARE1
Triglycerides	3.21	2	2	4.4	0.00	1.0e+00	NRBF2 SIDT2
Ulcerative Colitis	1.91	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Blood Eosinophil Count	1.47	7	7	15.6	-0.17	7.2e-01	CDK2AP1 CKM NEK4 PLCL2 SIDT2 SUOX TMED5
Blood Platelet Count	3.53	8	6	13.3	-0.25	5.6e-01	CDK2AP1 CKM MEF2C MPP6 NRBF2 SIDT2 TMED5 WDR24
Blood Red Count	1.30	13	10	22.2	0.28	3.6e-01	AP001877.1 CAMKMT CHST10 CKM CTC-498M16.2 LIN52 MED8 MEF2C NRBF2 PLCL2 SULT1A1 SUOX TMED5
Blood White Count	1.84	12	9	20.0	0.64	2.4e-02	CKM CTC-498M16.2 GPX1 MED8 MFSD10 MPP6 NRBF2 PPA2 RBM6 SIDT2 SLC5A11 TEX15
Heel T-Score	0.86	4	2	4.4	0.72	2.8e-01	CDK2AP1 NEGR1 NEK4 SLC5A11
BMI	4.68	18	15	33.3	0.70	1.2e-03	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MEF2C MFSD10 NEGR1 NEK4 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Height	1.85	20	14	31.1	-0.69	7.2e-04	AP001877.1 CAMKMT CDK2AP1 CTNNAL1 ELOVL7 GPX1 LIN52 MED8 MPP6 NEK4 NRBF2 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SIDT2 SLC5A11 TMED5 WDR24
Waist Hip Ratio (WHR)	2.08	8	4	8.9	0.36	3.8e-01	CDK2AP1 CTNNAL1 ELOVL7 GPX1 NEK4 PLCL2 RBL2 RSRC2
Systolic Blood Pressure	2.22	10	6	13.3	0.45	1.9e-01	GPX1 MED8 MPP6 NEK4 PPP2R2D RSRC2 SIDT2 SLC5A11 ST6GAL2 TSNARE1
Smoking Status	4.36	15	6	13.3	0.97	1.5e-09	CELF2 CKM ELOVL7 GPX1 IFT57 MED8 MEF2C MFSD10 NEK4 PLCL2 RBM6 RP11-7O11.3 SLC5A11 SUOX WDR24
Allergy or Eczema	2.69	7	3	6.7	-0.68	9.6e-02	CDK2AP1 CTB-75G16.3 NEGR1 PLCL2 SULT1A1 SUOX TMED5
Cardiovascular Disease	2.39	6	2	4.4	-0.10	8.5e-01	MED8 NEGR1 RBL2 SIDT2 SULT1A1 TEX15
Hypothyroidism (self reported)	2.02	2	2	4.4	0.00	1.0e+00	SIDT2 SUOX
Respiratory disease	1.92	1	1	2.2	0.00	1.0e+00	SUOX
Type 2 Diabetes (T2D) (2018)	1.64	1	0	0.0	0.00	1.0e+00	RBL2
Lung FEV1/FVC ratio	1.67	7	4	8.9	0.12	8.0e-01	GPX1 LIN52 NEGR1 NRBF2 PPA2 SLC5A11 SUOX
Lung FVC	1.21	5	3	6.7	0.42	4.8e-01	BCDIN3D GPX1 MFSD10 NRBF2 SUOX
Neuroticism	2.54	6	2	4.4	0.61	1.9e-01	B3GALTL CTC-498M16.2 GPX1 PLCL2 SIDT2 TSNARE1
Chronotype (morning person)	2.23	4	0	0.0	0.63	3.7e-01	CAMKMT DBN1 LIN52 SYPL2
Hair Pigment	0.14	2	1	2.2	0.00	1.0e+00	CDK2AP1 SUOX
Hand grip strength (left)	1.40	3	2	4.4	0.00	1.0e+00	NEK4 NPM3 SLC5A11
Number of treatments/medications taken	3.12	6	2	4.4	0.75	8.8e-02	B3GALTL GPX1 NEGR1 PPP2R2D RBM6 ST6GAL2
Sensitivity / hurt feelings	1.61	1	0	0.0	0.00	1.0e+00	PLCL2
Frequency of depressed mood in last 2 weeks	2.03	2	0	0.0	0.00	1.0e+00	CELF2 PLCL2
Relative age of first facial hair	1.38	2	0	0.0	0.00	1.0e+00	MED8 NRBF2
Ever used hormone-replacement therapy (HRT)	1.60	1	0	0.0	0.00	1.0e+00	BCDIN3D
Systolic blood pressure, automated reading	2.78	7	4	8.9	0.65	1.1e-01	GPX1 MED8 MPP6 NEK4 PPA2 SLC5A11 TSNARE1
Supplements: Zinc	1.58	1	0	0.0	0.00	1.0e+00	NRBF2
Medication: Co-codamol	2.02	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Pack years adult smoking proportion	3.26	4	0	0.0	0.23	7.7e-01	BNIP3 GPX1 MFSD10 NRBF2
Impedance of leg (right)	2.29	11	5	11.1	-0.03	9.3e-01	AP001877.1 CTNNAL1 ELOVL7 GPX1 NEGR1 NEK4 PPA2 RBL2 RBM6 SULT1A1 SUOX
Leg fat-free mass (left)	2.76	16	10	22.2	0.04	8.7e-01	BCDIN3D CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Trunk fat percentage	3.32	12	7	15.6	0.64	2.4e-02	CHST10 CTB-75G16.3 GPX1 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Hand grip strength (right)	1.61	5	2	4.4	-0.14	8.3e-01	NEK4 NPM3 RBL2 SLC5A11 SULT1A1
Townsend deprivation index at recruitment	2.82	1	0	0.0	0.00	1.0e+00	CKM
Current tobacco smoking	3.59	1	0	0.0	0.00	1.0e+00	SLC5A11
Average weekly fortified wine intake	2.36	1	0	0.0	0.00	1.0e+00	SLC5A11
Maternal smoking around birth	3.69	4	1	2.2	-0.46	5.4e-01	CKM CTB-75G16.3 MED8 SLC5A11
Fed-up feelings	3.67	8	1	2.2	0.98	9.1e-06	B3GALTL CDK2AP1 GPX1 PLCL2 RBM6 SLC5A11 TEX15 THEM6
Frequency of unenthusiasm / disinterest in last 2 weeks	3.09	1	0	0.0	0.00	1.0e+00	GPX1
Taking other prescription medications	2.75	3	1	2.2	0.00	1.0e+00	B3GALTL GPX1 RBM6
Age when periods started (menarche)	2.66	7	5	11.1	0.65	1.1e-01	CTNNAL1 GPX1 MED8 NEGR1 NRBF2 RP11-7O11.3 SUOX
Qualifications: CSEs or equivalent	2.58	2	0	0.0	0.00	1.0e+00	GPX1 ST3GAL3
High blood pressure	2.53	8	0	0.0	0.56	1.5e-01	NEGR1 NRBF2 RBL2 RSRC2 SLC5A11 SUOX TEX15 TSNARE1
Hayfever, allergic rhinitis or eczema	2.60	6	1	2.2	-0.66	1.6e-01	CDK2AP1 NEGR1 PLCL2 SULT1A1 SUOX TMED5
Medication: Levothyroxine sodium	1.45	1	1	2.2	0.00	1.0e+00	SUOX
Sitting height	1.99	9	6	13.3	-0.97	2.1e-05	CAMKMT CDK2AP1 MED8 NEK4 PPA2 PPP2R2D RBL2 RSRC2 WDR24
Body mass index (BMI)	4.76	19	11	24.4	0.76	1.5e-04	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MEF2C MFSD10 MPP6 NEGR1 NEK4 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Impedance of leg (left)	2.35	12	7	15.6	0.00	9.9e-01	AP001877.1 CDK2AP1 ELOVL7 GPX1 MEF2C NEGR1 NEK4 PPA2 RBL2 RBM6 SULT1A1 SUOX
Leg predicted mass (left)	2.77	16	10	22.2	0.04	8.7e-01	BCDIN3D CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Trunk fat mass	3.47	11	9	20.0	0.57	7.0e-02	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Waist circumference	3.94	15	8	17.8	0.72	2.6e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Past tobacco smoking	2.63	4	0	0.0	-1.00	4.6e-03	CELF2 RP11-7O11.3 SUOX WDR24
Alcohol usually taken with meals	5.07	5	1	2.2	-0.98	8.6e-04	CHST10 ELOVL7 MED8 NEGR1 NRBF2
Nervous feelings	2.23	3	0	0.0	0.00	1.0e+00	B3GALTL CTC-498M16.2 TSNARE1
Frequency of tenseness / restlessness in last 2 weeks	2.14	2	2	4.4	0.00	1.0e+00	B3GALTL GPX1
Had other major operations	1.50	1	0	0.0	0.00	1.0e+00	PPA2
Forced vital capacity (FVC)	1.75	8	2	4.4	-0.99	4.4e-07	BCDIN3D GPX1 MFSD10 PPA2 PPP2R2D RBL2 RBM6 RSRC2
Mouth/teeth dental problems	2.28	1	0	0.0	0.00	1.0e+00	ELOVL7
Allergy	2.29	3	2	4.4	0.00	1.0e+00	CDK2AP1 NEGR1 SUOX
Pain all over the body in last month	2.58	1	0	0.0	0.00	1.0e+00	GPX1
Diabetes (self-reported)	1.87	2	0	0.0	0.00	1.0e+00	RBL2 ST6GAL2
Hayfever/allergic rhinitis (self-reported)	1.55	1	0	0.0	0.00	1.0e+00	SUOX
Medication: Simvastatin	1.71	1	0	0.0	0.00	1.0e+00	SIDT2
Fluid intelligence score	8.15	26	11	24.4	-0.98	4.1e-19	BNIP3 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM CTB-75G16.3 GPX1 IFT57 MED8 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Illnesses of siblings	2.72	3	1	2.2	0.00	1.0e+00	RBL2 SLC5A11 ST3GAL3
Neuroticism score	2.41	4	2	4.4	0.99	1.3e-02	B3GALTL CELF2 GPX1 PLCL2
Weight	3.54	14	10	22.2	0.44	1.1e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 NEGR1 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Impedance of arm (right)	3.07	10	8	17.8	-0.47	1.4e-01	CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 NEK4 NRBF2 RBM6 SUOX SYPL2
Arm fat percentage (right)	3.92	14	8	17.8	0.68	7.7e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Trunk fat-free mass	2.43	14	9	20.0	-0.10	7.3e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Hip circumference	3.24	12	8	17.8	0.27	4.0e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 GPX1 NEGR1 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Alcohol intake versus 10 years previously	3.48	3	0	0.0	0.00	1.0e+00	GPX1 NEGR1 RP11-7O11.3
Father's age at death	2.32	2	0	0.0	0.00	1.0e+00	CDK2AP1 GPX1
Worrier / anxious feelings	2.44	4	1	2.2	0.65	3.5e-01	AP001877.1 B3GALTL NEK4 PLCL2
Frequency of tiredness / lethargy in last 2 weeks	2.35	1	0	0.0	0.00	1.0e+00	GPX1
Number of live births	1.76	1	0	0.0	0.00	1.0e+00	RBM6
Forced expiratory volume in 1-second (FEV1)	2.12	7	2	4.4	-0.70	8.2e-02	BCDIN3D GPX1 MFSD10 PPA2 PPP2R2D RBM6 SUOX
Pulse rate	1.21	1	0	0.0	0.00	1.0e+00	RBL2
Qualifications: A levels/AS levels or equivalent	10.38	30	16	35.6	-0.99	1.0e-24	AP001877.1 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM DBN1 ELOVL7 GPX1 IFT57 MED8 MPP6 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX THEM6 TMED5 TSNARE1 WDR24
Mouth/teeth dental problems: Dentures	3.75	4	1	2.2	0.99	9.5e-03	BCDIN3D GPX1 RBM6 TMED5
Asthma	1.73	1	1	2.2	0.00	1.0e+00	SUOX
Medication: Cholesterol lowering	1.49	1	0	0.0	0.00	1.0e+00	SIDT2
Prospective memory result	2.70	1	0	0.0	0.00	1.0e+00	PLCL2
Illnesses of mother	1.75	1	0	0.0	0.00	1.0e+00	CTB-75G16.3
Forced expiratory volume in 1-second (FEV1), Best measure	2.17	6	3	6.7	-0.55	2.6e-01	GPX1 MFSD10 PLCL2 PPA2 RBM6 SUOX
Impedance of arm (left)	3.08	10	7	15.6	-0.74	1.5e-02	CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 NEK4 NRBF2 RBM6 SUOX
Arm fat mass (right)	4.25	14	9	20.0	0.67	9.2e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Trunk predicted mass	2.43	14	9	20.0	-0.10	7.1e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Standing height	2.08	16	11	24.4	-0.84	4.7e-05	CAMKMT CDK2AP1 GPX1 MED8 MFSD10 MPP6 NEK4 NRBF2 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SIDT2 SLC5A11 WDR24
Exposure to tobacco smoke at home	2.21	1	0	0.0	0.00	1.0e+00	GPX1
Breastfed as a baby	2.23	1	0	0.0	0.00	1.0e+00	CDK2AP1
Seen doctor (GP) for nerves, anxiety, tension or depression	2.32	2	1	2.2	0.00	1.0e+00	B3GALTL NEGR1
Birth weight of first child	2.17	2	1	2.2	0.00	1.0e+00	PPA2 SUOX
Ever highly irritable/argumentative for 2 days	2.40	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Qualifications: O levels/GCSEs or equivalent	7.86	18	3	6.7	-0.98	8.3e-13	AP001877.1 CAMKMT CDK2AP1 CKM CTB-75G16.3 ELOVL7 GPX1 IFT57 MFSD10 MPP6 NRBF2 PLCL2 PPP2R2D RP11-7O11.3 ST3GAL3 ST6GAL2 THEM6 TSNARE1
Medication: Paracetamol	2.13	2	0	0.0	0.00	1.0e+00	GPX1 TMED5
Headache pain in last month	1.30	1	0	0.0	0.00	1.0e+00	SUOX
Hypothyroidism/myxoedema (self-reported)	1.86	2	1	2.2	0.00	1.0e+00	SIDT2 SUOX
Medication: Ventolin 100micrograms inhaler	1.49	1	0	0.0	0.00	1.0e+00	SUOX
Birth weight	1.69	1	0	0.0	0.00	1.0e+00	PPA2
High blood pressure (siblings)	2.37	1	0	0.0	0.00	1.0e+00	SLC5A11
Forced vital capacity (FVC), Best measure	1.83	8	2	4.4	-0.65	8.2e-02	BCDIN3D GPX1 MFSD10 PPA2 RBL2 RBM6 RSRC2 SUOX
Body fat percentage	4.02	15	9	20.0	0.69	4.1e-03	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6
Leg fat percentage (right)	5.28	20	10	22.2	0.78	5.6e-05	BNIP3 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6 TSNARE1 WDR24
Arm fat-free mass (right)	2.68	13	11	24.4	0.09	7.7e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Exposure to tobacco smoke outside home	3.00	2	0	0.0	0.00	1.0e+00	ELOVL7 RBM6
Comparative body size at age 10	3.14	7	4	8.9	0.03	9.5e-01	BCDIN3D CTB-75G16.3 CTC-498M16.2 MEF2C NEGR1 RBM6 SULT1A1
Number of full brothers	1.91	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Worry too long after embarrassment	2.20	3	0	0.0	0.00	1.0e+00	BCDIN3D DBN1 THEM6
Wheeze or whistling in the chest in last year	2.52	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Reason for reducing amount of alcohol drunk: Health precaution	2.05	2	0	0.0	0.00	1.0e+00	CTC-498M16.2 SUOX
Age at first live birth	5.79	7	2	4.4	-0.96	5.0e-04	AP001877.1 GPX1 NRBF2 RBM6 RP11-7O11.3 SUOX WDR24
Health satisfaction	2.03	3	0	0.0	0.00	1.0e+00	GPX1 MFSD10 TSNARE1
Qualifications: College or University degree	12.87	39	32	71.1	-0.98	7.4e-29	AP001877.1 B3GALTL BCDIN3D BNIP3 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM CTB-75G16.3 CTC-498M16.2 DBN1 ELOVL7 GPX1 IFT57 MED8 MFSD10 MPP6 NEGR1 NPM3 NRBF2 PPA2 PPP2R2D RARS2 RBL2 RBM6 RP11-7O11.3 RSRC2 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 THEM6 TMED5 TSNARE1 WDR24
Medication for pain relief, constipation, heartburn	2.45	4	1	2.2	-0.34	6.6e-01	CDK2AP1 GPX1 ST6GAL2 TEX15
Neck or shoulder pain in last month	1.64	2	0	0.0	0.00	1.0e+00	GPX1 SUOX
Medication: Blood pressure	1.94	1	0	0.0	0.00	1.0e+00	NEK4
Mean time to correctly identify matches	1.56	1	0	0.0	0.00	1.0e+00	IFT57
Whole body fat mass	4.06	14	9	20.0	0.65	1.1e-02	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Leg fat mass (right)	4.85	16	10	22.2	0.71	2.1e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Arm predicted mass (right)	2.69	13	11	24.4	0.11	7.0e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Pulse rate, automated reading	1.69	4	2	4.4	0.58	4.2e-01	CTC-498M16.2 NEGR1 RBL2 SLC5A11
Alcohol intake frequency.	4.16	10	3	6.7	0.80	6.0e-03	B3GALTL BNIP3 CDK2AP1 CTC-498M16.2 NEGR1 RBM6 SULT1A1 TEX15 TSNARE1 WDR24
Comparative height size at age 10	2.13	12	9	20.0	-0.73	7.1e-03	BCDIN3D CAMKMT CDK2AP1 MED8 NEK4 RBL2 RBM6 RP11-7O11.3 RSRC2 SULT1A1 TMED5 WDR24
Suffer from 'nerves'	1.95	3	0	0.0	0.00	1.0e+00	B3GALTL CTC-498M16.2 SULT1A1
Overall health rating	5.53	12	7	15.6	0.97	1.2e-07	B3GALTL CKM GPX1 MFSD10 NRBF2 PPP2R2D RBL2 RBM6 SLC5A11 TEX15 THEM6 TSNARE1
Age at last live birth	4.35	3	2	4.4	0.00	1.0e+00	AP001877.1 GPX1 RBM6
Leg pain on walking	1.72	1	0	0.0	0.00	1.0e+00	GPX1
Commuting to job workplace: Car/motor vehicle	1.60	1	0	0.0	0.00	1.0e+00	NEGR1
Hypertension (Self-reported)	2.58	7	1	2.2	0.62	1.4e-01	NEGR1 NRBF2 RBL2 SLC5A11 SUOX TEX15 TSNARE1
Whole body fat-free mass	2.58	14	11	24.4	-0.06	8.4e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Leg fat-free mass (right)	2.68	16	10	22.2	-0.14	5.9e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Arm fat percentage (left)	3.80	15	7	15.6	0.68	5.7e-03	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Average weekly red wine intake	5.10	7	2	4.4	-0.98	7.1e-05	AP001877.1 CAMKMT CDK2AP1 CTC-498M16.2 NRBF2 RBM6 RP11-7O11.3
Handedness (chirality/laterality): Left-handed	1.46	1	0	0.0	0.00	1.0e+00	SULT1A1
Mood swings	2.87	5	1	2.2	0.99	1.1e-03	CELF2 GPX1 PLCL2 RBM6 SLC5A11
Loneliness, isolation	2.03	1	0	0.0	0.00	1.0e+00	GPX1
Long-standing illness, disability or infirmity	1.80	1	0	0.0	0.00	1.0e+00	NEGR1
Diabetes diagnosed by doctor	1.70	1	0	0.0	0.00	1.0e+00	RBL2
Friendships satisfaction	1.84	1	0	0.0	0.00	1.0e+00	AP001877.1
Qualifications: nursing, teaching	7.18	9	3	6.7	-0.99	1.3e-07	B3GALTL CDK2AP1 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RP11-7O11.3 ST3GAL3
Mouth/teeth dental problems: Mouth ulcers	1.51	1	0	0.0	0.00	1.0e+00	AP001877.1
Medication for cholesterol	1.90	1	0	0.0	0.00	1.0e+00	RBL2
Mineral and other dietary supplements	2.22	1	0	0.0	0.00	1.0e+00	CTC-498M16.2
Asthma (self-reported)	1.76	2	1	2.2	0.00	1.0e+00	CDK2AP1 SUOX
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.71	1	0	0.0	0.00	1.0e+00	PPA2
Whole body water mass	2.60	14	11	24.4	-0.06	8.4e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Leg predicted mass (right)	2.66	15	10	22.2	-0.16	5.6e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 NEGR1 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Arm fat mass (left)	4.13	14	9	20.0	0.67	9.0e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Number of self-reported non-cancer illnesses	1.99	1	1	2.2	0.00	1.0e+00	NEGR1
Average weekly champagne plus white wine intake	3.63	2	0	0.0	0.00	1.0e+00	SULT1A1 WDR24
Miserableness	3.38	4	3	6.7	1.00	3.9e-03	B3GALTL CELF2 GPX1 RBM6
Guilty feelings	1.89	1	0	0.0	0.00	1.0e+00	GPX1
Financial situation satisfaction	2.23	1	1	2.2	0.00	1.0e+00	GPX1
Commuting to job workplace: Public transport	2.83	2	0	0.0	0.00	1.0e+00	CHST10 NEGR1
High cholesterol (Self-reported)	1.67	1	1	2.2	0.00	1.0e+00	SIDT2
Medication: Bendroflumethiazide	1.82	1	1	2.2	0.00	1.0e+00	TEX15
Medication: Paracetamol	2.05	2	0	0.0	0.00	1.0e+00	GPX1 TMED5
Medication: Atorvastatin	1.59	1	0	0.0	0.00	1.0e+00	SIDT2
Ever smoked	2.44	2	0	0.0	0.00	1.0e+00	CDK2AP1 WDR24
Basal metabolic rate	2.81	15	11	24.4	0.11	6.8e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Leg fat percentage (left)	5.30	20	11	24.4	0.78	5.6e-05	BNIP3 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6 TSNARE1 WDR24
Arm fat-free mass (left)	2.85	14	11	24.4	0.14	6.2e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Number of operations (self-reported)	2.11	2	0	0.0	0.00	1.0e+00	PPA2 RBM6
Average weekly beer plus cider intake	3.04	2	0	0.0	0.00	1.0e+00	NRBF2 RBM6
Ever had prostate specific antigen (PSA) test	1.67	1	0	0.0	0.00	1.0e+00	CTC-498M16.2
Age started oral contraceptive pill	2.06	2	0	0.0	0.00	1.0e+00	GPX1 IFT57
Diastolic blood pressure, automated reading	2.81	9	5	11.1	0.70	3.5e-02	CDK2AP1 GPX1 MED8 MPP6 NRBF2 SLC5A11 ST6GAL2 THEM6 TSNARE1
Unable to work because of sickness or disability	3.20	2	0	0.0	0.00	1.0e+00	ELOVL7 SLC5A11
Vascular/heart problems diagnosed by doctor	2.68	9	1	2.2	-0.47	2.0e-01	MED8 NEGR1 NRBF2 RBL2 RSRC2 SLC5A11 SUOX TEX15 TSNARE1
Cholesterol lowering medication	2.10	1	0	0.0	0.00	1.0e+00	SIDT2
Pain experienced in last month	2.88	3	1	2.2	0.00	1.0e+00	GPX1 RBM6 SUOX
Pack years of smoking	2.93	2	0	0.0	0.00	1.0e+00	GPX1 MFSD10
Impedance of whole body	2.83	13	9	20.0	-0.41	1.5e-01	CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 MEF2C NEGR1 NEK4 NRBF2 PPA2 RBM6 SUOX SYPL2
Leg fat mass (left)	4.88	16	10	22.2	0.71	2.1e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Arm predicted mass (left)	2.89	14	12	26.7	0.15	6.0e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	17	0.49	2.2
GTEx	Adipose Visceral Omentum	11	0.54	2.3
GTEx	Adrenal Gland	4	0.27	2.0
GTEx	Artery Aorta	17	0.57	2.2
GTEx	Artery Coronary	2	0.17	2.2
GTEx	Artery Tibial	26	0.69	2.2
GTEx	Brain Caudate basal ganglia	5	0.54	2.2
GTEx	Brain Cerebellar Hemisphere	9	0.60	2.4
GTEx	Brain Cerebellum	10	0.50	2.3
GTEx	Brain Cortex	7	0.68	2.2
GTEx	Brain Frontal Cortex BA9	5	0.54	2.3
GTEx	Brain Hippocampus	2	0.38	2.2
GTEx	Brain Hypothalamus	1	0.17	2.0
GTEx	Brain Nucleus accumbens basal ganglia	3	0.35	2.3
GTEx	Brain Putamen basal ganglia	3	0.48	2.2
GTEx	Breast Mammary Tissue	13	0.66	2.3
GTEx	Breast Mammary Tissue (Male)	3	0.25	2.1
GTEx	Breast Mammary Tissue (Female)	12	0.73	2.3
GTEx	Cells EBV-transformed lymphocytes	5	0.35	2.2
GTEx	Cells Transformed fibroblasts	24	0.57	2.2
GTEx	Colon Sigmoid	9	0.62	2.4
GTEx	Colon Transverse	12	0.58	2.2
GTEx	Esophagus Gastroesophageal Junction	7	0.48	2.3
GTEx	Esophagus Mucosa	19	0.57	2.2
GTEx	Esophagus Muscularis	22	0.68	2.3
GTEx	Heart Atrial Appendage	9	0.57	2.3
GTEx	Heart Left Ventricle	8	0.52	2.2
GTEx	Liver	3	0.42	2.2
GTEx	Lung	15	0.52	2.2
GTEx	Muscle Skeletal	18	0.62	2.3
GTEx	Nerve Tibial	24	0.56	2.2
GTEx	Ovary	5	0.55	2.3
GTEx	Pancreas	14	0.86	2.3
GTEx	Pituitary	4	0.36	2.2
GTEx	Prostate	5	0.60	2.2
GTEx	Skin Not Sun Exposed Suprapubic	16	0.65	2.3
GTEx	Skin Sun Exposed Lower leg	18	0.49	2.2
GTEx	Small Intestine Terminal Ileum	4	0.87	2.2
GTEx	Spleen	7	0.50	2.3
GTEx	Stomach	12	0.83	2.4
GTEx	Testis	14	0.44	2.3
GTEx	Thyroid	19	0.48	2.2
GTEx	Uterus	1	0.18	2.1
GTEx	Vagina	5	0.79	2.2
GTEx	Whole Blood	6	0.30	2.1
METSIM	Adipose	17	0.37	2.1
NTR	Blood	5	0.21	2.0
ROSMAP	Brain Pre-frontal Cortex	19	0.43	2.2
YFS	Blood	14	0.30	2.0
CommonMind	Brain Pre-frontal Cortex	16	0.30	2.1
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.42	2.1
The Cancer Genome Atlas	Breast Invasive Carcinoma	14	0.32	2.0
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.46	2.1
The Cancer Genome Atlas	Colon Adenocarcinoma	8	0.39	2.0
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.15	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	5	0.49	2.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	12	0.44	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.34	2.0
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	8	0.39	2.1
The Cancer Genome Atlas	Brain Lower Grade Glioma	16	0.37	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	8	0.72	2.1
The Cancer Genome Atlas	Lung Adenocarcinoma	14	0.48	2.1
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	10	0.40	2.0
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.38	2.0
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	11	0.66	2.1
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	7	0.53	2.1
The Cancer Genome Atlas	Prostate Adenocarcinoma	19	0.41	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.19	2.1
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.37	2.0
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.36	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.31	2.0
The Cancer Genome Atlas	Thyroid Carcinoma	17	0.33	2.0
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.0